ReviewNeurogastroenterology and motility2015
Emerging treatments in Neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist.
Review in Neurogastroenterology and motility, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 51 citations in OpenAlex.
- Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data.Alimentary pharmacology & therapeutics · 2020Trial
- Effects of ghrelin receptor agonist, relamorelin, on gastric motor functions and satiation in healthy volunteers.Neurogastroenterology and motility · 2016Trial
- Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial.Digestive diseases and sciences · 2016Trial
- HighRes_Builder: improved access and modeling of noncanonical residues for protein structure prediction.Briefings in bioinformatics · 2026Article
- Unlocking the Potential of Obestatin: A Novel Peptide Intervention for Skeletal Muscle Regeneration and Prevention of Atrophy.Molecular biotechnology · 2024Review
- Review
- Relamorelin in Gastroparesis and Diabetic Gastroparesis: A Meta-Analysis on Its Efficacy and Safety.Cureus · 2023Review
- Diabetic Gastroparesis and its Emerging Therapeutic Options: A Narrative Review of the Literature.Cureus · 2023Review
- Reconsideration of the Gastroparetic Syndrome.Current gastroenterology reports · 2023Review
- Strategic Approaches to Improvise Peptide Drugs as Next Generation Therapeutics.International journal of peptide research and therapeutics · 2023Review
- Parkinson's Disease and Current Treatments for Its Gastrointestinal Neurogastromotility Effects.Current treatment options in gastroenterology · 2018Review
- Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.Movement disorders : official journal of the Movement Disorder Society · 2018Review
- A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research.Frontiers in pharmacology · 2018Review
- Anti-emetic Action of the Brain-Penetrating New Ghrelin Agonist, HM01, Alone and in Combination With the 5-HTFrontiers in pharmacology · 2018Article
- In Search of the Ideal Promotility Agent: Optimal Use of Currently Available Promotility Agents for Nutrition Therapy of the Critically Ill Patient.Current gastroenterology reports · 2017Review
- Prokinetics in the Management of Functional Gastrointestinal Disorders.Current gastroenterology reports · 2017Review
- Gastroparesis: Medical and Therapeutic Advances.Digestive diseases and sciences · 2017Review
- Intractable Constipation in the Elderly.Current treatment options in gastroenterology · 2017Review
- Ghrelin and motilin receptors as drug targets for gastrointestinal disorders.Nature reviews. Gastroenterology & hepatology · 2016Review
- Ghrelin.Molecular metabolism · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundSynthetic ghrelin agonists, predominantly small molecules, are being developed as prokinetic agents that may prove useful in the treatment of gastrointestinal motility disorders. Relamorelin (RM-131) is a pentapeptide synthetic ghrelin analog that activates the growth hormone secretagogue (GHS)-1a (also called the ghrelin) receptor with approximately sixfold greater potency than natural ghrelin. The ability of relamorelin to stimulate growth hormone (GH) release is comparable to that of native ghrelin. Relamorelin has enhanced efficacy and plasma stability compared to native ghrelin. PURPOSE: In this review, we discuss the pharmacokinetics, pharmacodynamics and potential indications for relamorelin. Relamorelin is administered subcutaneously, dosed daily or twice daily. Relamorelin is being studied for the treatment of patients with gastrointestinal motility disorders. Phase IIA pharmacodynamic studies have demonstrated acceleration of gastric emptying in patients with type 1 diabetes mellitus (T1DM) and type 2 DM (T2DM) and upper gastrointestinal symptoms. In a phase IIA study in patients with diabetic gastroparesis, relamorelin accelerated gastric emptying and significantly improved vomiting frequency compared to placebo and improved other symptoms of gastroparesis in a prespecified subgroup of patients with vomiting at baseline. In patients with chronic idiopathic constipation with defined transit profile at baseline, relamorelin relieved constipation and accelerated colonic transit compared to placebo. These characteristics suggest that this new ghrelin analog shows great promise to relieve patients with upper or lower gastrointestinal motility disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.